SWAP-4

Acronym: Switching from Ticagrelor to Clopidogrel in Patients with Coronary Artery Disease

Purpose: Evaluation of the pharmacodynamic effects of switching patients with coronary artery disease from ticagrelor (Brilinta, AstraZeneca) to clopidogrel

Format: Randomized, open-label, parallel-assignment

Treatment Group: Ticagrelor 90 mg

Control Group: Clopidogrel

Number of Participants: 87

Center: Single

Inclusion Criteria: Patients with coronary artery disease

Summary: In all assays at all time points, ticagrelor 90 mg twice daily conferred lower platelet reactivity than any clopidogrel regimen. P2Y12 reaction unit levels did not significantly differ between those who took a clopidogrel 600-mg loading dose 24 hours after stopping ticagrelor and those who took clopidogrel 75 mg per day 24 hours after stopping ticagrelor (P = .29). P2Y12 reaction unit levels were lower in patients who took a clopidogrel 600-mg loading dose 12 hours after stopping ticagrelor vs. those who took clopidogrel 75 mg per day 24 hours after stopping ticagrelor (P = .024).

Original Publication: